Paris, March 7 2023 – iPSirius, a leading biotechnology company focused on the development of innovative immunotherapies, announced that it has been granted its second American patent for a novel technology that enables the production of ‘off-the-shelf’ cancer vaccines from induced pluripotent stem cells (iPSCs).
The newly granted patent covers the proprietary methods developed by iPSirius for the production of their proprietary IPVAC off-the-shelf cancer vaccines. The first patent granted to the company in the USA currently allows the preparation of a pre-IND and the Company sees the extension of its American patent portfolio as significant to its efforts to scale its clinical and manufacturing programs over the coming years.
“We are thrilled to have been granted our second American patent for this groundbreaking technology,” said Prof. Frank Griscelli, co-founder of iPSirius. “This is a major milestone for our company and further validates the potential of iPSC-based cancer vaccines to transform the treatment of a wide range of cancers. Our proprietary IPVAC technology is a key part of our pipeline of innovative cancer vaccines, and we are excited to continue developing and optimizing this technology to advance the field of cancer immunotherapy.”
iPSirius has a strong pipeline of innovative off-the-shelf cancer vaccines in development, based on their proprietary IPVAC technology. With this new patent, the company has strengthened its position as a leader in the rapidly growing fields of cancer immunotherapy and iPSC therapeutics.
iPSirius is a biotechnology company focused on the development of innovative immunotherapies using induced pluripotent stem cells (iPSCs). The company’s proprietary technology, named IPVAC, uses iPSCs to generate ‘off-the-shelf’ cancer vaccines. The company has also patents for its novel technology worldwide. In late 2022, the company recently received $2M from the European Innovation Council [More] and in 2023 appointed a COO to oversee first in-human trials.